Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
multiple sclerosis
Biotech
Tiziana prioritizes lowest hanging fruit, shelves unripe assets
Tiziana Life Sciences is following biotech’s quarter-three cull trend, putting several of its pipeline programs on the shelf.
Gabrielle Masson
Nov 10, 2022 2:56pm
Merck KGaA showcases durability of evobrutinib in MS
Oct 26, 2022 10:21am
Genentech aims to change 'one size' approach to MS trials
Sep 27, 2022 10:00am
Clene claims MS drug win, but data leaves questions
Aug 15, 2022 10:37am
Labcorp debuts blood test for several neurodegenerative diseases
Jul 13, 2022 11:01am
Atara stock plunges after inconclusive phase 2 data analysis
Jul 13, 2022 8:00am
